Articles from AGC Biologics

AGC Biologics, your friendly CDMO expert, today announced a strategic decision about the large-scale single-use technology it will use at its new Yokohama, Japan facility. The CDMO is introducing two 5,000 L Thermo Scientific DynaDrive Single-Use Bioreactors (S.U.B.), which makes the site one of the most advanced in Japan for large-scale mammalian-based biologics production, with GMP operations beginning in 2027.

AGC Biologics, your friendly CDMO expert, today announced the formation of a new Cell and Gene Technologies Division designed to focus and elevate existing AGC Biologics capabilities and further foster the company's performance as the most reliable, experienced and friendly advanced therapy CDMO worldwide.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the company won two awards from the annual CDMO Leadership awards, sponsored by Outsourced Pharma and Life Science Connect. AGC Biologics was named a winner in both the “Biologics – Global” and “Cell & Gene – Global” categories and is one of the few in the industry that scored high enough to be honored in multiple categories.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced that the team at its Milan site has received a special mention for Research and Innovation led by Executives Under the Age of 40, one of six special mentions in the Business Prize for Innovation by Confindustria. Confindustria is the main association representing manufacturing and service companies in Italy, with a voluntary membership of more than 150,000 companies of all sizes, employing a total of 5,383,286 people.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new service agreement with Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard). Under the agreement, AGC Biologics is providing autologous production for a next-generation-therapy product focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at the CDMO’s Heidelberg, Germany site.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a Lentiviral vector (LVV) expansion to its AGCellerate program designed to deliver GMP material for clinical trials in an accelerated timeline. The AGCellerate LVV offering guarantees developers 1e11 total transduction units (TU) of LVV material in nine months.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a capacity update with the addition of three new Grade B cell therapy suites to its Longmont, CO facility.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new agreement with Asahi Kasei Pharma Corporation to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site. The expansion added 1 x 50L 2 x 200L and 2 x 1,000L suspension single-use bioreactors, and allows for the addition of up to four iCellis500 adherent single-use bioreactors to meet demands for cGMP viral vector manufacturing projects. In addition, the project included the build-out of more process development lab space, a new automated filling line and the addition of a new fully dedicated 1,000m2 warehouse space.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced AGCellerate, a new program designed to deliver effective IND-ready GMP material for biopharmaceutical developers. AGCellerate offers guaranteed amounts at fixed timelines and costs – accelerating projects through development and into clinical phases.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the launch of its BravoAAV and ProntoLVV viral vector platforms. Leveraging three decades of Lentiviral vector (LVV) and Adeno-Associated Viral vector (AAV) development, manufacturing and analytical experience, AGC Biologics’ new platforms offer fast, efficient and reproducible clinical and commercial GMP production and release. The CDMO’s proprietary process and capsid-specific platform methods can accelerate development timelines, delivering GMP product in nine months.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has received the “Bioprocessing Excellence in Japan” award at the Asia-Pacific Bioprocessing Excellence Awards ceremony for the work and achievements at the AGC Biologics Chiba, Japan site.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it signed a service agreement with The Jikei University in Japan. Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site. The CDMO is producing TZIELD™ (teplizumab-mzwv), a new T1D treatment from Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.

GORE® Protein Capture Devices and AGC Biologics development and manufacturing platforms help advance downstream purification and support effective development and manufacturing

Seattle, Oct. 13, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has been named a 2022 Leading Innovator in Mammalian Cell Line Development for the USA by Acquisition International.  

The CDMO’s Milan facility provides lentiviral vector and autologous CD34+ cell-based drug products for clinical testing